Navigating Atopic Dermatitis Complexities and the Role of Topical Therapies - Society of Dermatology Physician Assistants

Gina Mangin, MPAS, PA-C, discusses how developing an effective atopic dermatitis treatment plan requires a personalized, multifaceted approach that combines proper skin care, trigger avoidance, topical medications, and potentially systemic therapies based on the severity of symptoms and individual patient needs.

Gina Mangin, MPAS, PA-C, discusses how identifying atopic dermatitis triggers involves carefully tracking patient exposure to common irritants such as soaps, fabrics, allergens, stress, and environmental factors while monitoring symptom flare-ups to develop targeted prevention strategies.

Gina Mangin, MPAS, PA-C, discusses how measuring atopic dermatitis treatment success requires evaluating multiple factors, including reduction in itch intensity, improvement in sleep quality, decreased flare frequency, enhanced quality of life, and visible skin healing through standardized assessment tools and patient-reported outcomes.

A panelist discusses how atopic dermatitis presents and is managed differently in adults vs children, with adults typically experiencing more localized lesions and chronic lichenification while children tend to have more widespread involvement and acute inflammation.

A panelist discusses how the choice between systemic and topical treatments for pediatric atopic dermatitis (AD) depends on factors such as disease severity, impact on quality of life, affected body surface area, and response to previous therapies.

The panelist discusses how ruxolitinib treats atopic dermatitis by inhibiting Janus kinase (JAK)1/JAK2 signaling pathways to reduce inflammation and alleviate symptoms of the skin condition.

The panelist discusses how to effectively communicate with patients about nonsteroidal topical treatment options for atopic dermatitis, including their benefits, proper application methods, and expected outcomes.

The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.

A panelist discusses how the choice between systemic and topical treatments for atopic dermatitis patients should be based on factors like disease severity, affected body surface area, impact on quality of life, and previous treatment response.

A panelist discusses how health care providers can address patients’ concerns about topical treatment side effects in atopic dermatitis by providing education about proper application, expected outcomes, and the strong safety profile of modern topical medications.

A panelist discusses how combining different therapeutic approaches, such as topical agents with systemic medications, can provide optimal control for patients with severe atopic dermatitis while managing both acute flares and long-term disease maintenance.

A panelist discusses how recent innovations in topical cream formulations for atopic dermatitis have led to improved efficacy, better tolerability, and enhanced quality of life for patients.